JERSEY CITY, N.J. (PRWEB) July 08, 2020
In its ongoing commitment to maintaining compliance with ever-changing global clinical trial disclosure regulations, Boehringer Ingelheim has renewed its partnership with TrialScope for an additional five years. More specifically, the company has renewed its license for use of the TrialScope Disclose™ platform.
TrialScope is the global leader in clinical trial transparency, with 16 of the top 20 industry sponsors relying on TrialScope technology for trial disclosure management. Collectively, TrialScope customers are responsible for more than 40 percent of all industry trials on ClinicalTrials.gov and the EU-CTR.
A TrialScope customer since 2015, Boehringer Ingelheim has several hundreds of studies managed with the TrialScope Disclose platform.
“We are proud to partner with Boehringer Ingelheim, a company that makes its commitment to clinical trial transparency a top priority.” said Francine Lane, TrialScope Vice President for Global Transparency. “That commitment, as proven by its remarkable disclosure compliance, is a reflection of the value the company places on improving the health and quality of life of those impacted by its research. We look forward to helping foster even greater long-term success for Boehringer Ingelheim.”
For more information on TrialScope or TrialScope Disclose, visit TrialScope.com.
TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 16 of the top 20 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit TrialScope.com.
About Boehringer Ingelheim